



(51) International Patent Classification:

C12N 15/10 (2006.01) C07H 21/02 (2006.01)
C12N 15/67 (2006.01) C12P 19/34 (2006.01)

(21) International Application Number:

PCT/US2025/010301

(22) International Filing Date:

03 January 2025 (03.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/617,664 04 January 2024 (04.01.2024) US

(71) Applicant: **TRILINK BIOTECHNOLOGIES, LLC**
[US/US]; 10770 Wateridge Circle, Suite 200, San Diego,
California 92121 (US).

(72) Inventors: **XU, Chunping**; c/o TriLink BioTechnologies,
LLC, 10770 Wateridge Circle, Suite 200, San Diego,
California 92121 (US). **ZHAO, Chanfeng**; c/o TriLink
BioTechnologies, LLC, 10770 Wateridge Circle, Suite 200,
San Diego, California 92121 (US). **LUDFORD III, Paul
Theodore**; c/o TriLink BioTechnologies, LLC, 10770 Wa-

teridge Circle, Suite 200, San Diego, California 92121 (US).
VENUGOPAL, Dhamodharan; c/o TriLink BioTech-
nologies, LLC, 10770 Wateridge Circle, Suite 200, San
Diego, California 92121 (US). **LEBEDEV, Alexandre V.**;
c/o TriLink BioTechnologies, LLC, 10770 Wateridge Cir-
cle, Suite 200, San Diego, California 92121 (US). **LANG,
Hengyuan**; c/o TriLink BioTechnologies, LLC, 10770 Wa-
teridge Circle, Suite 200, San Diego, California 92121 (US).

(74) Agent: **BREIER, Adam M.** et al.; McNeill PLLC, 245 First
Street, 18th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION




FIG. 12

(57) Abstract: Described herein are modified RNA molecules where a 3'-stabilizing region is covalently attached to the RNA, and where the 3'-stabilizing region comprises one or more modified nucleosides. Methods of synthesizing said RNAs are also provided herein.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

07 August 2025 (07.08.2025)